IN OTHER WORDS...

By Oren Rawls

Published December 12, 2003, issue of December 12, 2003.
  • Print
  • Share Share

Prescription for Disaster: “While much of the nation has been following the deliberations in Congress over a Medicare drug benefit, a quiet revolution has been taking place in the way benefits are managed for the 200 million Americans who already have insurance for prescription drugs,” Cindy Parks Thomas announces in the December 4 issue of the venerable New England Journal of Medicine.

Gone, at least for the most part, are the days when those with insurance simply forked over a $5 co-payment to “take two and call me in the morning.” Today, nearly two-thirds of prescription drug plans have adopted “three-tier formularies,” under which enrollees usually pay $10 for generic drugs, $15 for preferred or low-cost brand-name drugs and $25 or more for non-preferred or expensive brand-name drugs.

In theory, incentive-based formularies encourage the insured to opt for lower-cost prescription drugs, cutting costs for health care plans that can then be passed on to the consumer. The only problem with the theory, writes Thomas, co-director of the Prescription Drug Analysis Group at Brandeis University’s Schneider Institute for Health Policy, is that it’s bunk.

“Researchers consistently report that regardless of the particular details, incentive-based formularies lead to higher out-of-pocket costs to consumers and to some patients’ going without prescription drugs,” she asserts. “The extent to which total savings are passed on to employers or consumers are largely unknown and remain highly guarded industry secrets.”

Thomas’s claim is backed up by research conducted by a team of health care professionals led by Haiden Huskamp, an assistant professor of health economics at Harvard Medical School; his team’s findings are presented in a separate article in the same issue. The article examines the effects of incentive-based formularies on prescription-drug utilization and spending. The authors draw cautionary conclusions that stand in marked contrast to the unabashed optimism with which President Bush this week signed into law legislation giving the elderly prescription drug coverage under Medicare.

“Different changes in formulary administration may have dramatically different effects on utilization and spending and may in some instances lead enrollees to discontinue therapy,” warns Huskamp. “The associated changes in copayments can substantially alter out-of-pocket spending by enrollees, the continuation of the use of medications and possibly the quality of care.”

Huskamp and his team found that when companies switched to a three-tier prescription drug plan, some workers simply stopped filling their prescriptions. Such formularies, the researchers found, particularly affected those with lower incomes or chronic diseases.

“When patients either switch medications or discontinue therapy, are they merely skipping therapy of marginal value, or are they forgoing treatment that is medically necessary?” Thomas asks. “The patient must determine which medications are crucial.”

A growing number of patients, according to a third article in the New England Journal of Medicine, have already determined that their health is too valuable to be left in the hands of the American pharmaceutical industry.

“In a grass-roots movement that has swelled to a stampede over the past several years, U.S. citizens are heading to Canada to buy cheaper prescription drugs,” reports Dr. Abigail Zuger, a correspondent for the medical journal. “They are crossing the border in person, by telephone, by fax and by modem, in numbers estimated at a million or more.”

According to research by Canada’s federal Patented Medicine Prices Review Board, prices of patented prescription drugs are, on average, 67% higher in the United States than in Canada. America’s neighbor to the north ties prices for new medications not only to the going rate for drugs already on the market, but also to the cost of other consumer goods.

Doctors fielding questions from patients about the legality and safety of filling prescriptions through Canadian outlets, Zuger cautions, may find themselves at a loss for answers. Health care providers are likely to face similar dilemmas concerning queries over incentive-based formularies, particularly in regard to Bush’s recently passed overhaul of Medicare. What is clear to many, though, is that the American health care system is sick — and in need of a second opinion.

“When it comes to efforts to understand the effect of formulary design on the utilization of and spending on drugs, the devil is in the details,” Huskamp diagnoses. “As three-tier formularies become increasingly prevalent, we need much greater knowledge about these details in order to reap the advantages in cost savings without causing deleterious consequences for patients.”






Find us on Facebook!
  • Undeterred by the conflict, 24 Jews participated in the first ever Jewish National Fund— JDate singles trip to Israel. Translation: Jews age 30 to 45 travelled to Israel to get it on in the sun, with a side of hummus.
  • "It pains and shocks me to say this, but here goes: My father was right all along. He always told me, as I spouted liberal talking points at the Shabbos table and challenged his hawkish views on Israel and the Palestinians to his unending chagrin, that I would one day change my tune." Have you had a similar experience?
  • "'What’s this, mommy?' she asked, while pulling at the purple sleeve to unwrap this mysterious little gift mom keeps hidden in the inside pocket of her bag. Oh boy, how do I answer?"
  • "I fear that we are witnessing the end of politics in the Israeli-Palestinian conflict. I see no possibility for resolution right now. I look into the future and see only a void." What do you think?
  • Not a gazillionaire? Take the "poor door."
  • "We will do what we must to protect our people. We have that right. We are not less deserving of life and quiet than anyone else. No more apologies."
  • "Woody Allen should have quit while he was ahead." Ezra Glinter's review of "Magic in the Moonlight": http://jd.fo/f4Q1Q
  • Jon Stewart responds to his critics: “Look, obviously there are many strong opinions on this. But just merely mentioning Israel or questioning in any way the effectiveness or humanity of Israel’s policies is not the same thing as being pro-Hamas.”
  • "My bat mitzvah party took place in our living room. There were only a few Jewish kids there, and only one from my Sunday school class. She sat in the corner, wearing the right clothes, asking her mom when they could go." The latest in our Promised Lands series — what state should we visit next?
  • Former Israeli National Security Advisor Yaakov Amidror: “A cease-fire will mean that anytime Hamas wants to fight it can. Occupation of Gaza will bring longer-term quiet, but the price will be very high.” What do you think?
  • Should couples sign a pre-pregnancy contract, outlining how caring for the infant will be equally divided between the two parties involved? Just think of it as a ketubah for expectant parents:
  • Many #Israelis can't make it to bomb shelters in time. One of them is Amos Oz.
  • According to Israeli professor Mordechai Kedar, “the only thing that can deter terrorists, like those who kidnapped the children and killed them, is the knowledge that their sister or their mother will be raped."
  • Why does ultra-Orthodox group Agudath Israel of America receive its largest donation from the majority owners of Walmart? Find out here: http://jd.fo/q4XfI
  • Woody Allen on the situation in #Gaza: It's “a terrible, tragic thing. Innocent lives are lost left and right, and it’s a horrible situation that eventually has to right itself.”
  • from-cache

Would you like to receive updates about new stories?




















We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.